Synapse - Find an Expert

5608 Results

ARN-509 in men with metastatic castration-resistant prostate cancer (CRPC)

Meeting Abstract

Rathkopf, D.; Antonarakis, E. S.; Shore, N. D.; Tutrone, R.; Alumkal, J.; Ryan, C. J.; Saleh, M.; Hauke, R.; Chow-Maneval, E.; Scher, H. I.
Annals of Oncology (2012)

Fulltext@MSK | Save

Biomarkers of everolimus efficacy in patients with metastatic renal cell carcinoma (mRCC): Analysis of the phase III RECORD-1 trial

Meeting Abstract

Oudard, S.; Escudier, B.; Thompson, J.; Grünwald, V.; Conte, P. F.; Bracarda, S.; Panneerselvam, A.; Gogov, S.; Chen, D.; Motzer, R. J.
Annals of Oncology (2012)

Fulltext@MSK | Save

Tivozanib pharmacokinetic (PK)/pharmacodynamic (PD) analysis of blood pressure (BP) and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC)

Meeting Abstract

Nosov, D.; Motzer, R. J.; Loewy, J.; Hodge, L.; Esteves, B.; Berkenblit, A.; Yin, W.; Dykstra, K.; Hutson, T. E.; Cotreau, M.
Annals of Oncology (2012)

Fulltext@MSK | Save

Novel circulating proteins, single nucleotide polymorphisms (SNPs), and molecular tumor markers as potential biomarkers of sunitinib efficacy in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC)

Meeting Abstract

Motzer, R. J.; Hutson, T. E.; Hudes, G. R.; Figlin, R. A.; Martini, J.; English, P. A.; Wood, L.; Huang, X.; Valota, O.; Williams, J. A.
Annals of Oncology (2012)

Fulltext@MSK | Save

Axitinib vs sorafenib for advanced renal cell carcinoma: Phase III overall survival results and analysis of prognostic factors

Meeting Abstract

Motzer, R. J.; Escudier, B.; Tomczak, P.; Negrier, S.; Gore, M. E.; Tarazi, J.; Hariharan, S.; Rosbrook, B.; Kim, S.; Rini, B. I.
Annals of Oncology (2012)

Fulltext@MSK | Save

Phase I trial of ASG-5ME in metastatic castration resistant prostate cancer (CRPC)

Meeting Abstract

Morris, M.; Bruce, J.; Reyno, L.; Anand, B.; Hartford, A.; Jelaca-Maxwell, K.; Lackey, J.; Eisenberger, M.
Annals of Oncology (2012)

Fulltext@MSK | Save

A phase IB clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

Meeting Abstract

Molina, A. M.; Hutson, T. E.; Larkin, J.; Gold, A.; Andresen, C.; Wood, K.; Motzer, R. J.; Michaelson, M. D.
Annals of Oncology (2012)

Fulltext@MSK | Save

Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study

Meeting Abstract

Fizazi, K.; Scher, H. I.; Saad, F.; Sternberg, C. N.; Miller, K.; Mulders, P.; Chi, K.; Basch, E.; Hirmand, M.; de Bono, J. S.
Annals of Oncology (2012)

Fulltext@MSK | Save

Detailed comparison of the safety of tivozanib versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a phase 3 trial